Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-28T20:41:22.403Z Has data issue: false hasContentIssue false

Catatonia and neuroleptic malignant syndrome

Published online by Cambridge University Press:  02 January 2018

Robert Chaplin*
Affiliation:
Springfield Hospital, London SW17 7DJ
Rights & Permissions [Opens in a new window]

Abstract

Type
The Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 2002

Sir: Carey et al (Psychiatric Bulletin, February 2002, 26, 68-70) discussed the clinical issues surrounding a patient with features of catatonia and neuroleptic malignant syndrome (NMS). The relationship between the two conditions has been conceptualised in three ways. Castillo et al (Reference Castillo, Rubin and Holsboer-Trachsler1989) argue that lethal catatonia and NMS can be distinguished by clinical features, especially lead-pipe rigidity. Mann et al (Reference Mann, Caroff and Bleier1986) state that lethal catatonia is a syndrome that may have many causes, one of which is NMS. Bristow and Kohen (Reference Bristow and Kohen1996) regard catatonia as a risk factor for the development of NMS and lethal catatonia being identical to NMS.

The literature is less informative about the longitudinal features of both conditions. NMS recurs in a minority of patients and catatonia can recur. Although there is a consensus on the avoidance of neuroleptics in the acute stages of both conditions, there is little research to guide clinicians on their long-term management. The patient that the authors discussed experienced a relapse while treated with risperidone and lithium and they do not state the follow-up period after the second episode. The re-introduction of neuroleptic treatment after a near fatal episode of NMS or lethal catatonia appears to be associated with a high risk. Prospective data are needed on patients re-challenged with neuroleptics versus those in whom neuroleptics are withheld in order to help establish whether the conditions may be differentiated and to clarify the long-term risks and benefits of neuroleptic treatment.

References

Bristow, M. F. & Kohen, D. (1996) Neuroleptic malignant syndrome. British Journal of Hospital Medicine , 55, 517520.Google Scholar
Castillo, E., Rubin, R. T. & Holsboer-Trachsler, E. (1989) Clinical differentiation between lethal catatonia and neuroleptic syndrome. American Journal of Psychiatry, 146, 324328.Google Scholar
Mann, S. C., Caroff, S. N., Bleier, H. R. et al (1986) Lethal catatonia. American Journal of Psychiatry, 143, 13741381.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.